*****INFOCOMP VERIFICATION RATING
GRADE AHIGH CONFIDENCE*****
SCOPE
Systematic analysis of regulatory capture in global biotech: 46 incidents across 9 jurisdictions during 2022–2026.
Contents
DATA OVERVIEW
46 incidents, 57% growth since 2022. Total exposure: $5.7B.
PATTERNS
9 operational models. Dominant: shell companies in Zurich, biotech procurement through intermediaries.
RISK
57% of networks active. Risk: HIGH in 9 jurisdictions.
[i]9K Network Intelligence Disclosure
METHODOLOGY: This report was generated using 9K Network InfoComp automated intelligence system, drawing from open-source intelligence (OSINT) databases, public regulatory filings, and verified international reporting. All sources are publicly available. See our Intelligence Standards & Verification Policy for details.
